Relypsa (RLYP) : Money flow in the Relypsa (RLYP) stock was negative (1.19 million) on Friday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $12.53 million, compared to $13.72 million on downticks. The total uptick to downtick ratio was 0.91, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($4.02 million), indicating selling on the strength. The transaction value during uptick in block trades was $0.56 million. Downtick transaction value in block trades amounted to $4.58 million, indicating persistent selling. The uptick to downtick ratio was 0.12. Relypsa (RLYP) traded $0.08 higher at $32.03 gaining 0.23% over the previous days close.
Relypsa (RLYP) : The highest level Relypsa (RLYP) is projected to reach is $51 for the short term and the lowest estimate is at $9. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $30.56 and the possibility the share price can swing is $12.39.
Relypsa (NASDAQ:RLYP): stock turned positive on Friday. Though the stock opened at $31.85, the bulls momentum made the stock top out at $32.07 level for the day. The stock recorded a low of $31.85 and closed the trading day at $32.07, in the green by 0.38%. The total traded volume for the day was 13,218,946. The stock had closed at $31.95 in the previous days trading.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Relypsa Inc, Torley Helen had sold 1,013 shares worth of $19,571 in a transaction dated June 7, 2016. In this transaction, 1,013 shares were sold at $19.32 per share.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.